The psychedelic medicine market is rapidly expanding, with investors taking note. Psychedelic ventures have already announced a new $5 million fund to support psychedelic medicine start-ups. So, what does this mean for the industry as a whole and for those looking to capitalize on its growth potential?
Psychedelic medicine has been making a comeback in recent years as researchers study the potential benefits of substances like LSD, psilocybin, and MDMA. In light of this resurgence, a few start-ups have decided to focus on psychedelics as a part of their business model. But is this a smart move?
It’s no secret that mental health is a pressing issue, with one in four people experiencing a mental health disorder each year. What’s more, these disorders cost the global economy $2.5 trillion annually. Despite this, there has been a lack of investment in psychedelic medicine research and development.
From Silicon Valley to the streets of Manhattan, psychedelics are on the rise. Recently, several American investors have put their money into psychedelic ventures to unlock the therapeutic potential of psychedelics and capitalize on their growing popularity.